The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Combination Polyene‐Caspofungin Treatment of Rhino‐Orbital‐Cerebral Mucormycosis
Open accessAbstract
BACKGROUND: It has been axiomatic that echinocandins (e.g., caspofungin) are ineffective against mucormycosis. However, on the basis of preclinical data, we recently began treating rhino-orbital-cerebral mucormycosis (ROCM) with combination polyene-caspofungin therapy. METHODS: To determine the impact of polyene-caspofungin therapy, ROCM cases identified by an International Classification of Diseases, Ninth Revision search were retrospectively reviewed to gather data on demographic characteristics, clinical history, and outcomes. The predefined primary end point was success (i.e., the patients was alive and not in hospice care) at 30 days after hospital discharge. RESULTS: Forty-one patients with biopsy-proven ROCM were identified over 12 years; 23 (56%) of these patients were Hispanic, and 34 (83%) were diabetic. Patients treated with polyene-caspofungin therapy (6 evaluable patients) had superior success (100% vs. 45%; Pp.02) and Kaplan-Meier survival time (Pp.02), compared with patients treated with polyene monotherapy. Patients treated with amphotericin B lipid complex had inferior success (37% vs. 72%; Pp.03) and a higher clinical failure rate (45% vs. 21%; Pp.04), compared with patients who received other polyenes. However, patients treated with amphotericin B lipid complex plus caspofungin had superior success (100% vs. 20%; Pp.009) and survival time (Pp.01), compared with patients who received amphotericin B lipid complex alone. The benefit of combination therapy, compared with monotherapy, was most pronounced in patients with cerebral involvement (success rate, 100% vs. 25%; Pp.01). In multivariate analysis, only receipt of combination therapy was significantly associated with improved outcomes (odds ratio, 10.9; 95% confidence interval, 1.3- ;Pp.02). CONCLUSIONS: Combination polyene-caspofungin therapy represents a promising potential alternative to polyene monotherapy for patients with ROCM. Randomized, prospective investigation of these findings is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
Roden, M. M., Zaoutis, T. E., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., Schaufele, R. L., Sein, M., Sein, T., Chiou, C. C., Chu, J. H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432579 · Cited by 3,044
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Self-citationNovel perspectives on mucormycosis: pathophysiology, presentation, and management
Spellberg, B., Edwards, J., & Ibrahim, A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.3.556-569.2005 · Cited by 1,537
Self-citationEpidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002) · Clinical Infectious Diseases · doi:10.1086/339202 · Cited by 1,448
Dectin-1 is required for β-glucan recognition and control of fungal infection
Taylor, P. R., Tsoni, S. V., Willment, J. A., Dennehy, K. M., Rosas, M., Findon, H., Haynes, K., Steele, C., Botto, M., Gordon, S., et al. (2007) · Nature Immunology · doi:10.1038/ni1408 · Cited by 1,161
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Espinel-Ingroff, A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2950-2956.1998 · Cited by 576
Zygomycosis in the 1990s in a Tertiary-Care Cancer Center
Kontoyiannis, D. P., Wessel, V. C., Bodey, G. P., & Rolston, K. V. I. (2000) · Clinical Infectious Diseases · doi:10.1086/313803 · Cited by 521
Groll, A. H., Giri, N., Petraitis, V., Petraitiene, R., Candelario, M., Bacher, J. S., Piscitelli, S. C., & Walsh, T. J. (2000) · The Journal of Infectious Diseases · doi:10.1086/315643 · Cited by 373
Kurtz, M. B., Heath, I. B., Marrinan, J., Dreikorn, S., Onishi, J., & Douglas, C. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.7.1480 · Cited by 320
Bowman, J. C., Hicks, P. S., Kurtz, M. B., Rosen, H., Schmatz, D. M., Liberator, P. A., & Douglas, C. M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.3001-3012.2002 · Cited by 303
Pfaller, M. A., Marco, F., Messer, S. A., & Jones, R. N. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00246-0 · Cited by 241
Caspofungin: the first representative of a new antifungal class
Letscher-Bru, V. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg117 · Cited by 235
Improved Outcome of Zygomycosis in Patients with Hematological Diseases?
Gleissner, B., Schilling, A., Anagnostopolous, I., Siehl, I., & Thiel, E. (2004) · Leukemia & Lymphoma · doi:10.1080/10428190310001653691 · Cited by 227
Ibrahim, A. S., Bowman, J. C., Avanessian, V., Brown, K., Spellberg, B., Edwards, J. E., & Douglas, C. M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.721-727.2005 · Cited by 207
Self-citationStevens, D. A., Ichinomiya, M., Koshi, Y., & Horiuchi, H. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00563-06 · Cited by 193
Spellberg, B., Fu, Y., Edwards, J. E., & Ibrahim, A. S. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.830-832.2005 · Cited by 186
Self-citationCombination Echinocandin-Polyene Treatment of Murine Mucormycosis
Ibrahim, A. S., Gebremariam, T., Fu, Y., Edwards, J. E., & Spellberg, B. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01458-07 · Cited by 180
Self-citationThe role of the β-glucan receptor Dectin-1 in control of fungal infection
Dennehy, K. M., & Brown, G. D. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.1206753 · Cited by 165
Del Poeta, M., Schell, W. A., & Perfect, J. R. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.8.1835 · Cited by 164
Chiou, C. C., Mavrogiorgos, N., Tillem, E., Hector, R., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3310-3321.2001 · Cited by 117
Combination Therapy for Invasive Aspergillosis
Viscoli, C. (2004) · Clinical Infectious Diseases · doi:10.1086/423389 · Cited by 48
Kinoshita, K., Iwasaki, H., Uzui, H., & Ueda, T. (2006) · Translational research · doi:10.1016/j.trsl.2006.07.001 · Cited by 15
Cited by
Cornely, O. A., Alastruey-Izquierdo, A., Arenz, D., Chen, S. C. A., Dannaoui, E., Hochhegger, B., Hoenigl, M., Jensen, H. E., Lagrou, K., Lewis, R. E., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30312-3 · Cited by 1,820
Self-citationEpidemiology and Clinical Manifestations of Mucormycosis
Petrikkos, G., Skiada, A., Lortholary, O., Roilides, E., Walsh, T. J., & Kontoyiannis, D. P. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir866 · Cited by 1,452
Global Epidemiology of Mucormycosis
Prakash, H., & Chakrabarti, A. (2019) · Journal of Fungi · doi:10.3390/jof5010026 · Cited by 938
ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
Cornely, O. A., Arikan-Akdagli, S., Dannaoui, E., Groll, A. H., Lagrou, K., Chakrabarti, A., Lanternier, F., Pagano, L., Skiada, A., Akova, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12371 · Cited by 863
Tissot, F., Agrawal, S., Pagano, L., Petrikkos, G., Groll, A. H., Skiada, A., Lass-Flörl, C., Calandra, T., Viscoli, C., & Herbrecht, R. (2017) · Haematologica · doi:10.3324/haematol.2016.152900 · Cited by 682
Metadata
- Authors
- Reed, C., Bryant, R., Ibrahim, A. S., Edwards, Jr., Filler, S. G., Goldberg, R., & Spellberg, B.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-08
- Volume
- 47
- Issue
- 3
- Pages
- 364-371
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2171789838
- Cited by
- 494
- References
- 23
- FWCI
- 22.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.